CD274 and gastric adenocarcinoma: Tumour mutation burden, tumour immunosuppressive microenvironment, and PD-L1 expression are strongly associated with the response to immune-checkpoint inhibitors.7,8 In addition, the advantages of these inhibitors in improving prognostic outcomes in STAD has been shown to vary with different patient ethnicities, different immune-checkpoint inhibitor categories, microsatellite instability, and tumour mutational burden.9 Furthermore, many genetic biomarkers currently ignore clinical pathological features and do not reflect the immune status of patients.